Improved tumor-to-organ ratios of a novel 67Ga-human epidermal growth factor radionuclide conjugate with preadministered antiepidermal growth factor receptor affibody molecules

Cancer Biotherapy and Radiopharmaceuticals

Volumn 26, Issue 5, 2011, Pages 593-601

  Sandström, Karl ^a   Haylock, Anna Karin ^a   Velikyan, Irina ^a,b   Spiegelberg, Diana ^a   Kareem, Heewa ^a   Tolmachev, Vladimir ^a   Lundqvist, Hans ^a   Nestor, Marika ^a  

^a UPPSALA UNIVERSITY   (Sweden)

^b BIACORE AB   (Sweden)

Author keywords

affibody molecule; EGFR; gallium; head and neck cancer; molecular imaging; tumor to organ ratio

Indexed keywords

EPIDERMAL GROWTH FACTOR; GALLIUM 67; RADIOISOTOPE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; FEMALE; IN VITRO STUDY; IN VIVO STUDY; ISOTOPE LABELING; MOUSE; NONHUMAN; ONCOLOGICAL PARAMETERS; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR TO ORGAN RATIO; TUMOR XENOGRAFT;

ANIMALS; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; FEMALE; GALLIUM RADIOISOTOPES; HEAD AND NECK NEOPLASMS; HUMANS; MICE; MICE, INBRED BALB C; MICE, NUDE; ORGANOMETALLIC COMPOUNDS; RADIOPHARMACEUTICALS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECOMBINANT FUSION PROTEINS; TISSUE DISTRIBUTION; TRANSPLANTATION, HETEROLOGOUS;

EID: 80054709746     PISSN: 10849785     EISSN: 15578852     Source Type: Journal    
DOI: 10.1089/cbr.2011.0981     Document Type: Article

References (33)

1. Grandis JR, Tweardy DJ. Elevated levels of transforming growth factor alpha and epidermal growth factor receptor messenger RNA are early markers of carcinogenesis in head and neck cancer. Cancer Res 1993;53:3579.
2. Ekberg T, Nestor M, Engstrom M, et al. Expression of EGFR, HER2, HER3, and HER4 in metastatic squamous cell carcinomas of the oral cavity and base of tongue. Int J Oncol 2005;26:1177.
3. Lee JW, Soung YH, Kim SY, et al. Somatic mutations of EGFR gene in squamous cell carcinoma of the head and neck. Clin Cancer Res 2005;11:2879.
4. Loeffler-Ragg J, Witsch-Baumgartner M, Tzankov A, et al. Low incidence of mutations in EGFR kinase domain in Caucasian patients with head and neck squamous cell carcinoma. Eur J Cancer 2006;42:109.
5. Chung CH, Parker JS, Karaca G, et al. Molecular classification of head and neck squamous cell carcinomas using patterns of gene expression. Cancer Cell 2004;5:489-500. (Pubitemid 38610250)
6. Rubin Grandis J, Melhem MF, Gooding WE, et al. Levels of TGF-alpha and EGFR protein in head and neck squamous cell carcinoma and patient survival. J Natl Cancer Inst 1998; 90:824.
7. Störkel S, Reichert T, Reiffen KA, et al. EGFR and PCNA experession in oral squamous cell carcinomas-a valuable tool in estimating the patient's prognosis. Eur J Cancer Part B: Oral Oncol 1993;29:273.
8. Kumar B, Cordell KG, Lee JS, et al. Response to therapy and outcomes in oropharyngeal cancer are associated with bio-markers including human papillomavirus, epidermal growth factor receptor, gender, and smoking. Int J Radiat Oncol Biol Phys 2007;69(2 suppl):S109.
9. Ang KK, Berkey BA, Tu X, et al. Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma. Cancer Res 2002;62:7350.
10. Eriksen JG, Steiniche T, Overgaard J. The influence of epidermal growth factor receptor and tumor differentiation on the response to accelerated radiotherapy of squamous cell carcinomas of the head and neck in the randomized DA-HANCA 6 and 7 study. Radiother Oncol 2005;74:93.
11. Bentzen SM, Atasoy BM, Daley FM, et al. Epidermal growth factor receptor expression in pretreatment biopsies from head and neck squamous cell carcinoma as a predictive factor for a benefit from accelerated radiation therapy in a randomized controlled trial. J Clin Oncol 2005;23:5560.
12. Baum RP, Prasad V, Muller D, et al. Molecular imaging of HER2-expressing malignant tumors in breast cancer patients using synthetic 111In-or 68Ga-labeled affibody molecules. J Nucl Med 2010;51:892.
13. Reilly RM, Kiarash R, Sandhu J, et al. A comparison of EGF and MAb 528 labeled with 111In for imaging human breast cancer. J Nucl Med 2000;41:903.
14. Cuartero-Plaza A, Martinez-Miralles E, Rosell R, et al. Radiolocalization of squamous lung carcinoma with 131I-labeled epidermal growth factor. Clin Cancer Res 1996;2:13.
15. Velikyan I, Sundberg AL, Lindhe O, et al. Preparation and evaluation of (68)Ga-DOTA-hEGF for visualization of EGFR expression in malignant tumors. J Nucl Med 2005;46:1881.
16. Tolmachev V, Rosik D, Wallberg H, et al. Imaging of EGFR expression in murine xenografts using site-specifically labelled anti-EGFR 111In-DOTA-Z EGFR:2377 Affibody molecule: aspect of the injected tracer amount. Eur J Nucl Med Mol Imaging 2010;37:613.
17. Divgi CR, Welt S, Kris M, et al. Phase I and imaging trial of indium 111-labeled anti-epidermal growth factor receptor monoclonal antibody 225 in patients with squamous cell lung carcinoma. J Natl Cancer Inst 1991;83:97.
18. Hu M, Scollard D, Chan C, et al. Effect of the EGFR density of breast cancer cells on nuclear importation, in vitro cyto-toxicity, and tumor and normal-tissue uptake of [111In]-DTPA-hEGF. Nucl Med Biol 2007;34:887.
19. Kareem H, Sandstrom K, Elia R, et al. Blocking EGFR in the liver improves the tumor-to-liver uptake ratio of radio-labeled EGF. Tumour Biol 2010;31:79.
20. Tolmachev V, Orlova A, Wei Q, et al. Comparative biodis-tribution of potential anti-glioblastoma conjugates [111In]-DTPA-hEGF and [111In]Bz-DTPA-hEGF in normal mice. Cancer Biother Radiopharm 2004;19:491.
21. Nord K, Nilsson J, Nilsson B, et al. A combinatorial library of an alpha-helical bacterial receptor domain. Protein Eng 1995;8:601.
22. Lofblom J, Feldwisch J, Tolmachev V, et al. Affibody molecules: engineered proteins for therapeutic, diagnostic and biotechnological applications. FEBS Lett 2010;584:2670.
23. Nordberg E, Orlova A, Friedman M, et al. In vivo and in vitro uptake of 111In, delivered with the affibody molecule (ZEGFR:955)2, in EGFR expressing tumour cells. Oncol Rep 2008;19:853-857. (Pubitemid 351802651)
24. Tolmachev V, Friedman M, Sandstrom M, et al. Affibody molecules for epidermal growth factor receptor targeting in vivo: aspects of dimerization and labeling chemistry. J Nucl Med 2009;50:274.
25. Levashova Z, Backer MV, Horng G, et al. SPECT and PET imaging of EGF receptors with site-specifically labeled EGF and dimeric EGF. Bioconjug Chem 2009;20:742.
26. Velikyan I, Sundin A, Eriksson B, et al. In vivo binding of [68Ga]-DOTATOC to somatostatin receptors in neuroendo-crine tumours-impact of peptide mass. Nucl Med Biol 2010;37:265.
27. Velikyan I, Maecke H, Langstrom B. Convenient preparation of 68Ga-based PET-radiopharmaceuticals at room temperature. Bioconjug Chem 2008;19:569.
28. Friedman M, Nordberg E, Hoiden-Guthenberg I, et al. Phage display selection of Affibody molecules with specific binding to the extracellular domain of the epidermal growth factor receptor. Protein Eng Des Sel 2007;20:189.
29. Friedman M, Orlova A, Johansson E, et al. Directed evolution to low nanomolar affinity of a tumor-targeting epidermal growth factor receptor-binding affibody molecule. J Mol Biol 2008;376:1388.
30. Velikyan I, Beyer GJ, Bergstrom-Pettermann E, et al. The importance of high specific radioactivity in the performance of (68)Ga-labeled peptide. Nucl Med Biol 2008; 35:529.
31. Nordberg E, Friedman M, Gostring L, et al. Cellular studies of binding, internalization and retention of a radiolabeled EGFR-binding affibody molecule. Nucl Med Biol 2007; 34:609.
32. Nordberg E, Ekerljung L, Sahlberg SH, et al. Effects of an EGFR-binding affibody molecule on intracellular signaling pathways. Int J Oncol 2010;36:967.
33. Gostring L, Chew MT, Orlova A, et al. Quantification of internalization of EGFR-binding Affibody molecules: Methodological aspects. Int J Oncol 2010;36:757.